ES2196213T3 - Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3. - Google Patents

Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3.

Info

Publication number
ES2196213T3
ES2196213T3 ES97107580T ES97107580T ES2196213T3 ES 2196213 T3 ES2196213 T3 ES 2196213T3 ES 97107580 T ES97107580 T ES 97107580T ES 97107580 T ES97107580 T ES 97107580T ES 2196213 T3 ES2196213 T3 ES 2196213T3
Authority
ES
Spain
Prior art keywords
group
serotonine
receiver
sub
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97107580T
Other languages
English (en)
Inventor
Yasuo Sato
Megumi Yamada
Kazuko Kobayashi
Katsuyoshi Iwamatsu
Fukio Konno
Koichi Shudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Application granted granted Critical
Publication of ES2196213T3 publication Critical patent/ES2196213T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION PROPORCIONA UN ACTIVADOR PARCIAL DEL RECEPTOR DE SEROTONINA 5 PTOR DE SEROTONINA 5 TOR DE SEROTONINA 5 TO SECUNDARIO. EN PARTICULAR, SOBRE LA BASE DEL HALLAZGO DE QUE DERIVADOS DE BENZOXAZOL RECIENTEMENTE SINTETIZADOS TIPIFICADOS POR LOS COMPUESTOS DE FORMULA SIGUIENTE (2) TIENEN ACCION ANTAGONISTA INTENSA DEL RECEPTOR DE SEROTONINA 5-HT3 Y ACTIVADORA DEL RECEPTOR 5 OS DE BENZOXAZOL COMO ACTIVADORES PARCIALES DEL RECEPTOR DE SEROTONINA 5 PUEDEN SER IGUALES O DIFERENTES UNO DE OTRO Y CADA UNO REPRESENTA UN ATOMO DE HIDROGENO, UN ATOMO DE HALOGENO, UN GRUPO ALQUILO INFERIOR SUSTITUIDO O NO, UN GRUPO ALQUENILO INFERIOR SUSTITUIDO O NO, O UN GRUPO AMINO SUSTITUIDO O NO, O DOS GRUPOS R{SUB,1} Y R{SUB,2} PUEDEN ESTAR UNIDOS PARA FORMAR UNA ESTRUCTURA EN ANILLO, A SABER UN ANILLO DE BENCENO; R{SUB,5} REPRESENTA UN ATOMO DE HIDROGENO, UN GRUPO ALQUILO INFERIOR SUSTITUIDO O NO O UN GRUPO ALQUENILO INFERIOR SUSTITUIDO O NO; Y M ES UN NUMERO ENTERO DE 1 A 4.
ES97107580T 1996-05-09 1997-05-07 Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3. Expired - Lifetime ES2196213T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11500896 1996-05-09
JP09382197A JP3520177B2 (ja) 1996-05-09 1997-04-11 セロトニン５−ｈｔ３受容体部分活性薬

Publications (1)

Publication Number Publication Date
ES2196213T3 true ES2196213T3 (es) 2003-12-16

Family

ID=26435106

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97107580T Expired - Lifetime ES2196213T3 (es) 1996-05-09 1997-05-07 Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3.

Country Status (6)

Country Link
US (5) US6037342A (es)
EP (1) EP0806419B1 (es)
JP (1) JP3520177B2 (es)
KR (1) KR100426981B1 (es)
DE (1) DE69720317T2 (es)
ES (1) ES2196213T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3520177B2 (ja) 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
TW520370B (en) * 1998-11-20 2003-02-11 Meiji Seika Kaisha Benzooxazole derivatives and a pharmaceutical composition containing the derivatives as an active ingredient
EP1411052B1 (en) * 2001-07-05 2011-10-05 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
US6861533B2 (en) 2001-11-23 2005-03-01 Irm Llc Solution phase sythesis of arylbenzoxazoles
KR100544126B1 (ko) * 2003-08-26 2006-01-23 삼성에스디아이 주식회사 유기 전계 발광 소자 및 그 제조방법
WO2006022194A1 (en) * 2004-08-23 2006-03-02 Semiconductor Energy Laboratory Co., Ltd. Electron injecting composition, and light emitting element and light emitting device using the electron injecting composition
WO2006028161A1 (ja) * 2004-09-09 2006-03-16 Research Foundation Itsuu Laboratory セロトニン５－ｈｔ３受容体作動薬
US7771601B1 (en) * 2005-11-14 2010-08-10 Shepherd Samuel L Treatment of waste sludge with recycling
CN101410385B (zh) 2006-03-28 2011-08-24 高点制药有限责任公司 具有组胺h3受体活性的苯并噻唑类
EP3020718B1 (en) * 2013-07-10 2018-12-26 Meiji Seika Pharma Co., Ltd. Novel pde4 inhibitor
MX2019007684A (es) 2016-12-26 2019-09-09 Meiji Seika Pharma Co Ltd Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.
KR20210024563A (ko) 2018-06-27 2021-03-05 메이지 세이카 파루마 가부시키가이샤 염증성 질환, 자가면역 질환, 섬유화 질환 및 암 질환의 치료제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1228524A (es) * 1958-05-23 1960-08-31
SU417421A1 (es) * 1972-01-10 1974-02-28
ES2038532B1 (es) * 1991-05-10 1994-02-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de 2-piperacinilbecimidazol.
JP3193560B2 (ja) * 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
JP3520177B2 (ja) * 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
KR100901648B1 (ko) * 2002-06-29 2009-06-09 매그나칩 반도체 유한회사 반도체 소자의 제조 방법

Also Published As

Publication number Publication date
DE69720317D1 (de) 2003-05-08
EP0806419B1 (en) 2003-04-02
JPH1029987A (ja) 1998-02-03
DE69720317T2 (de) 2004-02-19
US6037342A (en) 2000-03-14
US20010016579A1 (en) 2001-08-23
KR19980079226A (ko) 1998-11-25
EP0806419A1 (en) 1997-11-12
US6552057B2 (en) 2003-04-22
KR100426981B1 (ko) 2004-09-01
US6867226B2 (en) 2005-03-15
JP3520177B2 (ja) 2004-04-19
US6333328B1 (en) 2001-12-25
US20030013730A1 (en) 2003-01-16
US6297246B1 (en) 2001-10-02

Similar Documents

Publication Publication Date Title
ES2159839T3 (es) Derivados del propano, su preparacion y su uso.
ES2196213T3 (es) Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3.
ES2108700T3 (es) Derivados de diazabiciclonolilo como antagonistas del receptor 5-ht3.
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2123829T3 (es) Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas.
ES2100187T3 (es) Derivados de carboestirilos y composiciones farmaceuticas que los contienen.
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PA8522001A1 (es) Pro - farmacos de derivados de 4- fenil - piridin.
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
ES2059327T3 (es) Derivados de tetrahidronaftaleno y de indano, obtencion de los mismos y utilizacion en preparados farmaceuticos.
AR029614A1 (es) Derivados de 4-fenil-piridina, su uso, un proceso para prepararlos, y medicamentos que los contienen
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
ES2052675T3 (es) 3-(4-piperazinil-sustituido en 1)butil)-4-tiazolidinonas, un procedimiento para su preparacion y su uso como medicamentos.
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
AR039651A1 (es) Derivados de isoquinolina
PE20020346A1 (es) Derivados de fenoxibencilamina como ssri
ES2175089T3 (es) Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.
ES2160106T3 (es) Derivados de la quinazolina.
ES2067874T3 (es) Derivados de acetamida.
ES2154470T3 (es) Derivados de tetrahidroisoquinolina y su uso farmaceutico.
ES2128668T3 (es) Agonistas del receptor de 5-ht4.
ES2038766T3 (es) 4-aril-5-carbamoil-1,4-dihidropiridinas.
ES2154605B1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3